

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

2843

In Re Application Of:

BOTHE, U., ET AL

Serial No.

10/735,487

Filing Date

12/12/2003

Examiner

Group Art Unit

Title: NEW GLUCOCORTICOID RECEPTOR...

Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

2843

In Re Application:

BOTHE, U., ET AL

Serial No.

10/735,487

Filing Date

12/12/2003

Examiner

Group Art Unit

NEW GLUCOCORTICOID RECEPTOR...

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☐ The Director is hereby authorized to charge and credit Deposit Account as described below.
- ☐ Charge the amount of _____
 - ☐ Credit any overpayment.
 - ☐ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____) on _____

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on FEB. 12, 2004 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature of Person Mailing Correspondence

MICHAEL J. STRIKER

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Dated: FEBRUARY 12, 2004

CC:



UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner:.

Group:

Attorney Docket # 2843

Applicant(s): BOTHE, U., ET AL

Serial No.: 10/735,487

Filed: 12/12/2003

For : NEW GLUCOCORTICOID RECEPTOR...

INFORMATION DISCLOSURE STATEMENT

February 11, 2004

Honorable Commissioner of Patents
and Trademarks
Washington, D.C. 20231


S I R S:

- _____ In accordance with the Duty of Disclosure, Applicant(s) submit(s) herewith a copy of a Foreign Search Report in a counterpart application and copies of the reference(s) indicated therein.
- _____ In the event that the Foreign Search Report is in a foreign language, a translation thereof is herewith submitted.
- ___X___ Attached hereto is a FORM PTO 1449 listing the references.
- ___X___ Attached hereto is a copy of a reference cited in the specification of the application as filed. The specification itself recites the relevance of these documents, and pursuant to M.P.E.P. Section 609 A (3) this represents an acceptable Statement of Relevancy. The reference(s) appear(s) at the following page(s) and line(s) of the specification: page 2 lines 13-15, 19 from the top and lines 1-9 from the bottom, Page 3 line 6-7 from the top.
- _____ Applicant petitions for consideration of this Information Disclosure Statement since it is being submitted after receipt of an office action. It is respectfully requested that the required fee be charged to the account of the undersigned: 19-4675.

page 2 of 2

- _____ Attached hereto are copies of references cited which may be pertinent to this application. Since the references are in the English language, no statement of relevancy is submitted.
- _____ Attached hereto is a copy of the Office Action issued in the corresponding German and European applications, together with a translation thereof and copies of the references cited therein. A list of the cited references is also attached.
- _____ Attached hereto copies of references cited which may be pertinent to this application. A Certified English translation of the reference is also attached.
- _____ Attached hereto is a Statement of Relevancy and copies of references cited therein.
- _____ The relevancy of each reference can be found in the English language Abstract attached thereto

Respectfully submitted,


Michael J. Striker
Attorney for Applicant(s)
Reg. No. 27233

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>	ATTY DOCKET NO. 2843	SERIAL NO. 10/735,487
	APPLICANT(S) BOTHE, U., ET AL	
	FILING DATE 12/12/2003	GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		0 683 172 A1	11/22/1995	EP			✓	
		0 793 541 B1	09/22/1999	EP				✓
		96/20795	07/11/1996	WO				✓
		01/47859 A1	07/05/2001	WO			✓	
		95/04536	02/16/1995	WO			✓	

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

			HATZ, H. J. GLUCOCORTICOIDE, P. 231, WISSENSCHAFTLICHE VERLAGSGESELLSCHAFT MBH, STUTTGART, 1998.
			MOGULEWSKY, M. PHILIBERT ET AL: "THE ANTIPROGESTIN STEROID...." P. 87-97, PLENUM PRESS, NEW YORK, LONDON 1984.


EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>	ATTY DOCKET NO. 2843	SERIAL NO. 10/735,487
	APPLICANT(S) BOTHE, U., ET AL	
	FILING DATE 12/12/2003	GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE



FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO
0 057 115 B1	03/20/1985	EP				<input checked="" type="checkbox"/>

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

			LYNNETTE K. NIEMAN ET AL: "SUCCESSFUL TREATMENT OF CUSHING'S SYNDROME...", J. CLIN. ENDORC. METAB. 6, VOL. 1, P. 536-540, 1985.
			R. GEBHARD ET AL: "11.21-BISPHENYL-19-NORPREGNANE...", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 7, PP. 2229-2234, 1997.

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

